FDA OKs Mazor's spinal deformity software for Surgical Assurance Platform; shares ahead 4% premarket

|About: Mazor Robotics Ltd. (MZOR)|By:, SA News Editor

Mazor Robotics (NASDAQ:MZOR) is up 4% premarket on light volume in response to its announcement that the FDA has approved its Mazor X Align software that supports its Mazor X Surgical Assurance Platform. The software is designed to assist surgeons in planning spinal deformity correction and spinal alignment procedures.

Selective roll-out will commence next month with full commercial launch to follow in H2.